It remains to be elucidated whether our findings with an elevated frequency of GFI1-36N in myeloma patients and its potential influence on the disease course of t(14;16) and gain 1q21, can be replicated in other independent cohorts. This evidence concerns the gene GFI1 and plasma cell myeloma.